United States Patent 7,638,522: What Is Claimed and How It Sits in the Patent Landscape
What does US 7,638,522 claim, in scope terms?
US 7,638,522 claims a specific pharmaceutical composition defined by (1) the presence and loading of a compound of formula (I-a) and (2) a carrier blend with tightly bounded excipient ranges.
Independent claim 1 (composition + carrier controls)
A. Active/load definition
- Compound of formula (I-a) present at 5% to 50% (w/w, implied) of the total pharmaceutical composition.
B. Carrier excipient definition
The claim requires a pharmaceutically acceptable carrier that contains, as percentages of the pharmaceutical composition:
- 0.01% to 5% wetting agent
- 40% to 92% diluent
- 0% to 10% polymer
- 2% to 10% disintegrant
- 0.1% to 5% glidant
- 0.1% to 1.5% lubricant
C. Structural function of the carrier controls
The claim is drafted so that the composition is within scope only if it falls inside the rectangular excipient range set and the active loading range simultaneously. Even if the compound of formula (I-a) is used, the product can fall outside claim scope if the excipient recipe is outside one or more limits.
Claim-scope implications
- The active is constrained to formula (I-a) and 5% to 50% loading.
- The carrier is constrained to a blend that totals across diluent and minor excipients with specified min/max bounds.
- Because carrier component ranges are mutually constrained, the claim is not merely “use of compound (I-a).” It is a formulation claim with hard numerical excipient limits.
How is the carrier range likely to control infringement risk?
The claim’s risk lever is the excipient recipe, not just the active.
| Carrier component bounds in Claim 1 |
Component |
Percent of composition |
Claim range |
| WETTING AGENT |
|
0.01% to 5% |
| DILUENT |
|
40% to 92% |
| POLYMER |
|
0% to 10% |
| DISINTEGRANT |
|
2% to 10% |
| GLIDANT |
|
0.1% to 5% |
| LUBRICANT |
|
0.1% to 1.5% |
| Active (I-a) |
|
5% to 50% |
Practical reading
- A generic formulation that uses formula (I-a) but changes excipients outside the ranges (for example, reducing disintegrant below 2% or using glidant above 5%) can avoid this claim even if all other elements match.
- Conversely, if the formulation sits within all ranges, the claim reads on it.
What does the claim language mean for design-around strategies?
Based on the structure of claim 1, the easiest design-around lever is excipient selection and quantity. A product using formula (I-a) still can be outside scope if any required range is not met.
Design-around vectors implied by claim structure
- Move one excipient outside range
Example categories: wetting agent, diluent, disintegrant, glidant, lubricant, or polymer.
- Change active loading
The claim requires formula (I-a) at 5% to 50%. Reformulate outside that window.
- Use a carrier that does not meet the numeric carrier composition
Even if “pharmaceutically acceptable carrier” exists, the claim ties it to specific component percentages.
Because claim 1 is an all-elements formulation claim, missing any range typically avoids literal scope.
What is the likely patent classification and what does it imply?
US formulation patents with excipient-by-percentage ranges typically fall under categories used for:
- solid oral dosage formulation compositions
- excipients and formulation technology
Even without claim-dependent text, the numerical carrier constraints indicate the invention is positioned as a formulation with defined excipient proportions rather than a purely chemical invention.
Landscape implication: the key competitive differentiator in this family is not the API alone; it is the formulation recipe boundaries. That tends to produce many subsequent filings from competitors around:
- alternative excipient systems
- alternative wetting/binding/disintegration/glidant/lubricant choices
- altered active loading to bypass range overlap
Where does US 7,638,522 tend to sit relative to process and method patents?
Given that the claim is explicitly a pharmaceutical composition, it likely competes most directly with:
- other formulation patents covering similar API(s) but with different excipient ranges
- downstream “same API different formulation” patents
- method-of-manufacture patents are less directly implicated unless they are tied to the same end product composition or include composition limitations
Key point: as a composition claim, US 7,638,522 is typically enforced against products (or product labeling and manufacturing disclosures) rather than processes alone.
Patent landscape: How to map competitive risk from this claim language
What search strategy is most relevant to this landscape?
A formulation claim of this structure is best mapped through:
- the API identity (formula I-a)
- the excipient range set (wetting agent 0.01 to 5; diluent 40 to 92; disintegrant 2 to 10; glidant 0.1 to 5; lubricant 0.1 to 1.5; polymer 0 to 10)
- the dosage form context likely used in the specification (tablets, granules, powders, etc.)
Since your provided excerpt does not include formula I-a identity, landscape mapping cannot reliably determine:
- the exact active chemical name
- the surrounding claim set for salts, polymorphs, and intermediates
- whether dependent claims lock into dosage forms, specific excipient species, particle size, granulation route, or dissolution specs
Given those missing elements, the only defensible landscape conclusions are those derived directly from the claim architecture: this is a formulation-range claim.
What types of later patents usually remain “in play” despite this claim?
Competitors often file around composition-range claims by changing at least one of the constrained variables.
Typically viable alternatives
- Same API (formula I-a), different excipient quantities that violate one required range.
- Same formulation concept, different disintegrant or glidant type if the later patent locks to different excipient species, even when total percentages overlap.
- Different active loading outside 5% to 50%.
- Different granulation/dosage-form architecture if later claims add extra product limitations that this claim does not include.
Likely to challenge risk
- Later patents that cover “core composition” ranges that still overlap all the bounded excipient ranges in claim 1 and also contain formula (I-a).
- Continuations or divisionals within the same family that refine formulation with narrower specs (for example, narrower diluent range or specific excipient combinations) that could still overlap if your target falls in-range.
Claims analysis beyond claim 1: what matters for scope
Why claim 1 is the dominant scope driver
If claim 1 is independent and does not limit to a specific dosage form (tablet/granule/capsule), it is the breadth anchor. Dependent claims may narrow by:
- specific wetting agent species
- specific diluent types and grade
- polymer function (binder vs coating)
- additional constraints like dissolution profile, hardness, friability, or tablet disintegration time
But with only claim 1 text provided, the enforceable scope that can be directly analyzed is:
- formula (I-a) at 5-50%
- carrier excipient percentages within the specified numeric ranges
Key Takeaways
- US 7,638,522 claim 1 is a formulation claim, requiring compound of formula (I-a) at 5% to 50% plus a carrier with tightly bounded excipient percentages: wetting agent 0.01-5%, diluent 40-92%, polymer 0-10%, disintegrant 2-10%, glidant 0.1-5%, lubricant 0.1-1.5%.
- Infringement risk is driven by excipient recipe: using formula (I-a) is necessary but not sufficient; falling outside even one excipient range can avoid literal scope.
- Design-around is structurally straightforward: change active loading outside 5-50% or push at least one excipient out of its claimed numeric window.
- Landscape mapping for this family should focus on formulation-range overlap (same API + excipient range sets), not only on chemical identity.
FAQs
-
Does US 7,638,522 cover use of formula (I-a) alone?
No. Claim 1 requires a full pharmaceutical composition meeting both the active loading (5-50%) and the carrier excipient percentage ranges.
-
If a product uses the same compound of formula (I-a), is it automatically infringing?
Not under claim 1. The product must also fit the carrier composition ranges and the active loading.
-
Which excipients are numerically constrained in claim 1?
Wetting agent, diluent, polymer, disintegrant, glidant, and lubricant are each constrained to specific min/max percentages.
-
Is the claim likely aimed at solid oral formulations?
The excipient set and ranges are typical of solid oral formulation strategy, but claim 1 text provided does not explicitly specify dosage form.
-
What is the fastest formulation lever to design around?
Adjust active loading outside 5-50% or adjust one or more excipient quantities outside the listed ranges.
References
[1] United States Patent 7,638,522, claim 1 (composition and excipient percentage ranges as provided).
